TCM
GTBP icon

Triumph Capital Management’s GT Biopharma GTBP Stock Holding History

Triumph Capital Management’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$810 Hold
1,655
– – ﹤0.01% 1685
2026
Q1 		$675 Hold
1,655
– – ﹤0.01% 1672
2025
Q4 		$1.3K Buy
+1,655
New +$1.18K ﹤0.01% 1534

Other funds holding GTBP

EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
AIS
AM Investment Strategies Chattanooga, Tennessee $521M AUM 33.22% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
MFA
Mayflower Financial Advisors Boston, Massachusetts $1.16B AUM 24.36% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
WFA
West Financial Advisors Des Moines, Iowa $659M AUM 17.93% 1-Year Est. Return
RFA
Reyes Financial Architecture San Diego, California $179M AUM 31.17% 1-Year Est. Return

Triumph Capital Management's GTBP Position: Q2 2026 in Review

Triumph Capital Management held its GT Biopharma (GTBP) position steady in Q2 2026 at 1,655 shares worth $810. The position accounts for ﹤0.01% of the portfolio, ranked #1685.

Triumph Capital Management first reported a position in GTBP in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.3K in Q4 2025. 12 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • Triumph Capital Management held 1,655 shares of GT Biopharma worth $810 as of Q2 2026.
  • Triumph Capital Management left its GT Biopharma share count unchanged in Q2 2026.
  • GT Biopharma made up ﹤0.01% of Triumph Capital Management's portfolio in Q2 2026, its #1685 holding.
  • Triumph Capital Management first reported a position in GT Biopharma in Q4 2025 and has held it in 3 quarters since.
  • Triumph Capital Management's GT Biopharma position peaked at $1.3K in Q4 2025.
  • 12 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.